Cardiopoietic Stem Cells for Heart Failure Therapy

Stem Cell and Gene Therapy for Cardiovascular Disease

Volumn , Issue , 2015, Pages 235-241

  Behfar, Atta ^a   Terzic, Andre ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cardiac regeneration; Cardiopoiesis; Heart failure; Lineage specification; Stem cells

Indexed keywords

EID: 84991547408     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-801888-0.00019-9     Document Type: Chapter

References (48)

1. Mozaffarian D., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015, 131:e29-e322.
2. Jahangir A., Sagar S., Terzic A. Aging and cardioprotection. J Appl Physiol 2007, 103:2120-2128.
3. Terzic A., Waldman S. Chronic diseases: the emerging pandemic. Clin Transl Sci 2011, 4:225-226.
4. Yancy C.W., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128:e240-327.
5. Feldman D., et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transpl 2013, 32:157-187.
6. Kittleson M.M., Kobashigawa J.A. Management of the ACC/AHA Stage D patient: cardiac transplantation. Cardiol Clin 2014, 32:95-112. viii.
7. Gries C.J., et al. An official American Thoracic Society/International Society for Heart and Lung Transplantation/Society of Critical Care Medicine/Association of Organ and Procurement Organizations/United Network of Organ Sharing Statement: ethical and policy considerations in organ donation after circulatory determination of death. Am J Respir Crit Care Med 2013, 188:103-109.
8. Bailey A.M., Mendicino M., Au P. An FDA perspective on preclinical development of cell-based regenerative medicine products. Nat Biotechnol 2014, 32:721-723.
9. Mendicino M., Bailey A.M., Wonnacott K., et al. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell 2014, 14:141-145.
10. Dimmeler S., Ding S., Rando T.A., et al. Translational strategies and challenges in regenerative medicine. Nat Med 2014, 20:814-821.
11. Terzic A., Harper C.M., Gores G.J., et al. Regenerative medicine blueprint. Stem Cells Dev 2013, 22(Suppl. 1):20-24.
12. Bergmann O., et al. Evidence for cardiomyocyte renewal in humans. Science 2009, 324:98-102.
13. van Deursen J.M. The role of senescent cells in ageing. Nature 2014, 509:439-446.
14. Tchkonia T., Zhu Y., van Deursen J., et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013, 123:966-972.
15. Behfar A., Terzic A. Stem cells versus senescence: the yin and yang of cardiac health. J Am Coll Cardiol 2015, 65:148-150.
16. Behfar A., Crespo-Diaz R., Terzic A., et al. Cell therapy for cardiac repair--lessons from clinical trials. Nat Rev Cardiol 2014, 11:232-246.
17. Bartunek J., Vanderheyden M., Hill J., et al. Cells as biologics for cardiac repair in ischaemic heart failure. Heart 2010, 96:792-800.
18. Behfar A., et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J 2002, 16:1558-1566.
19. Fisher S.A., et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev 2014, 4:CD007888.
20. Traverse J.H., et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 2012, 308:2380-2389.
21. Schachinger V., et al. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail 2009, 11:973-979.
22. Cogle C.R., et al. Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res 2014, 115:867-874.
23. Hagege A.A., et al. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation 2006, 114:I108-113.
24. Trainor N., Pietak A., Smith T. Rethinking clinical delivery of adult stem cell therapies. Nat Biotechnol 2014, 32:729-735.
25. Terzic A., Behfar A. Regenerative heart failure therapy headed for optimization. Eur Heart J 2014, 35:1231-1234.
26. Makkar R.R., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012, 379:895-904.
27. Chugh A.R., et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012, 126:S54-64.
28. Naylor R.M., Baker D.J., van Deursen J.M. Senescent cells: a novel therapeutic target for aging and age-related diseases. Clin Pharmacol Ther 2013, 93:105-116.
29. Hariharan N., et al. Nucleostemin rejuvenates cardiac progenitor cells and antagonizes myocardial aging. J Am Coll Cardiol 2015, 65:133-147.
30. Golpanian S., et al. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. J Am Coll Cardiol 2015, 65:125-132.
31. Behfar A., et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010, 56:721-734.
32. Behfar A., Terzic A. Stem cell in the rough: repair quotient mined out of a bone marrow niche. Circ Res 2014, 115:814-816.
33. Conboy I.M., et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005, 433:760-764.
34. Sanganalmath S.K., Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013, 113:810-834.
35. Behfar A., et al. Guided stem cell cardiopoiesis: discovery and translation. J Mol Cell Cardiol 2008, 45:523-529.
36. Behfar A., Terzic A. Mesenchymal stem cells: engineering regeneration. Clin Transl Sci 2008, 1:34-35.
37. Gersh B.J., Simari R.D., Behfar A., et al. Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc 2009, 84:876-892.
38. Bartunek J., Behfar A., Vanderheyden M., et al. Mesenchymal stem cells and cardiac repair: principles and practice. J Cardiovasc Transl Res 2008, 1:115-119.
39. Behfar A., et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med 2007, 204:405-420.
40. Behfar A., Terzic A. Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny. Nat Clin Pract Cardiovasc Med 2006, 3(Suppl. 1):S78-82.
41. Arrell D.K., Niederlander N.J., Faustino R.S., et al. Cardioinductive network guiding stem cell differentiation revealed by proteomic cartography of tumor necrosis factor alpha-primed endodermal secretome. Stem Cells 2008, 26:387-400.
42. Faustino R.S., Behfar A., Perez-Terzic C., et al. Genomic chart guiding embryonic stem cell cardiopoiesis. Genome Biol 2008, 9:R6.
43. Bartunek J., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013, 61:2329-2338.
44. Marban E., Malliaras K. Boot camp for mesenchymal stem cells. J Am Coll Cardiol 2010, 56:735-737.
45. Behfar A., Crespo-Diaz R., Terzic A., et al. Reply: Translation of regenerative technologies into clinical paradigms. Nature reviews. Cardiology 2014, 11:553-554.
46. Sheridan C. Cardiac stem cell therapies inch toward clinical litmus test. Nat Biotechnol 2013, 31:5-6.
47. Murry C.E., Palpant N.J., MacLellan W.R. Cardiopoietry in motion: primed mesenchymal stem cells for ischemic cardiomyopathy. J Am Coll Cardiol 2013, 61:2339-2340.
48. Telukuntla K.S., Suncion V.Y., Schulman I.H., et al. The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc 2013, 2:e000338.